Preclinical Trial-on-Chip Multi-Organ Linkage System Customization Service Powered CAR-T Development

Online Inquiry

Background Service What we can offer Workflow HighlightsFAQs Contact

Long development cycles, unpredictable toxicity, and limited solid tumor infiltration remain major challenges in CAR-T programs. Traditional models often fail to accurately recapitulate human physiology. Creative Biolabs' Preclinical Trial-on-Chip Multi-Organ Linkage System Customization addresses these limitations by providing advanced microphysiological systems that replicate human tumor microenvironments and multi-organ crosstalk. Utilizing precision-engineered microfluidic linkage technology, this service enables accelerated drug discovery, predictive evaluation of clinical safety, and mechanistic insight into CAR-T infiltration, efficacy, and systemic interactions.

Introduction

CAR-T therapy has emerged as a powerful tool in the treatment of various cancers. However, predicting its efficacy and safety in complex, multi-organ systems remain a significant challenge. The Preclinical Trial-on-Chip Multi-Organ Linkage System integrates several organ models to provide a more realistic simulation of the human body. This approach offers a deeper understanding of CAR-T cell behavior and systemic effects, ensuring better-informed clinical decisions.

Service

Creative Biolabs provides high-fidelity, customized microphysiological systems that move beyond simplistic 2D assays. By integrating multi-organ linkage, we allow you to evaluate not just how CAR-T cells kill tumor cells, but how they interact with healthy tissues and systemic circulation. This "Preclinical Trial-on-Chip" approach empowers you to identify the most potent and safest CAR constructs before entering human trials.

Creative Biolabs' Preclinical Trial-on-Chip Multi-Organ Linkage System offers a cutting-edge platform for testing CAR-T therapies in an environment that mimics human physiology. Key offerings include:

Multi-organ integration: Simulate interactions between CAR-T cells and various organ systems (liver, kidney, lungs, etc.), improving the accuracy of toxicity and efficacy predictions.
Customizable models: Tailored organ systems to match specific disease conditions or patient-derived tumor models, allowing for personalized medicine applications.
Real-time monitoring: Continuous data collection to evaluate the kinetics of CAR-T cell behavior, tumor targeting, and immune responses.

Discover How We Can Help - Request a Consultation to design a chip model.

What We Can Offer

Platforms of Preclinical Trial-on-Chip Multi-Organ Linkage System Customization. (Creative Biolabs Original)

Our Workflow

To initiate the service, clients typically provide Required Starting Materials such as specific CAR-T cell constructs, patient-derived tumor organoids, and specific target antigen data.

Workflow of Preclinical Trial-on-Chip Multi-Organ Linkage System Customization. (Creative Biolabs Original)

The final deliverables include comprehensive efficacy reports with quantitative data on tumor growth inhibition and T-cell infiltration, dynamic safety profiles analyzing cytokine release to predict CRS risks, and high-resolution imaging data featuring 3D confocal videos of CAR-T cell movement and tumor interaction.

Our Advantages

One-stop preclinical chip service from model design to multi-organ CAR-T evaluation.
Integration of hiPSC-derived organ barriers and primary human cells for physiological relevance.
High-throughput analysis, including real-time monitoring and cell transcriptional profiling.
Customizable organ-on-chip platforms for patient-derived tumor models and personalized medicine applications.
Experienced team ensuring rigorous quality control, reproducibility, and project guidance.

FAQs

Q1: How does this system compare to humanized mouse models for CAR-T testing?

A1: Our on-chip systems can be established in less than a week, whereas humanized mouse models often take several months. Additionally, our platform uses human-specific endothelial and stromal cells, avoiding the species-specific differences that often lead to inaccurate toxicity predictions in mice.

Q2: Can we monitor Cytokine Release Syndrome (CRS) on the chip?

A2: Yes. The linear perfusion allows for continuous sampling of effluents. We can monitor the kinetics of IL-2, IL-6, TNF-α, and IFN-γ to mimic the initial surges observed in clinical high-grade CRS.

Q3: Is it possible to test "safety switches" using this service?

A3: Absolutely. Our system supports pharmacological interventions. We have demonstrated the ability to test on/off switches to manage cytokine release without permanently diminishing antitumor efficacy.

Q4: What types of tumors can be modeled?

A4: We offer customization for both hematological malignancies and solid tumors, incorporating patient-derived organoids for high clinical relevance.

Partner with Us

Creative Biolabs provides a revolutionary Preclinical Trial-on-Chip Multi-Organ Linkage System that transforms how CAR-T therapies are validated. By combining microfluidic engineering with patient-specific biology, we provide the spatiotemporal data necessary to de-risk your pipeline and accelerate clinical translation. Our team of expert scientists is ready to assist with your customization needs. Whether you require a specific organ linkage or a high-throughput efficacy screen, we provide the technical rigor your project deserves. Contact Our Team for More Information and to Discuss Your Project.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.